Miyata Tatsunori, Okabe Hirohisa, Chikamoto Akira, Yamao Takanobu, Umezaki Naoki, Tsukamoto Masayo, Kitano Yuki, Arima Kota, Nakagawa Shigeki, Imai Katsunori, Hashimoto Daisuke, Yamashita Yo-Ichi, Baba Hideo
Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Surg Case Rep. 2017 Oct 16;3(1):110. doi: 10.1186/s40792-017-0386-z.
Although hilar cholangiocarcinoma (HCCA) has a very poor prognosis, there are cases in which long-term survival is rarely obtained by multidisciplinary treatment.
A 61-year-old man diagnosed with HCCA was referred to our hospital. We performed an extended left hemi-hepatectomy and caudate lobectomy with extrahepatic bile duct resection. The tumor stage was T2aN0M0, stage II, based on the TNM classification, seventh edition. R0 resection was successfully performed. Adjuvant chemotherapy was not administered. After 38 months, computed tomography revealed peritoneal dissemination. The patient received chemotherapy with tegafur-gimeracil-oteracil-potassium (S-1) and gemcitabine. The peritoneal dissemination was successfully controlled for more than 50 months. During the treatment, levels of CEA and CA19-9 kept rising slowly, which was followed by bowel obstruction due to peritoneal dissemination of HCCA. The patient underwent resection of transverse colon with tumor nodules, and the tumor was pathologically diagnosed as metastasis of HCCA. Tumor markers decreased to normal levels, and the patient has been free from tumor relapse for 6 months.
We here report a rare case of HCCA patient with recurrent peritoneal dissemination 3 years after R0 surgery which was sensitive to chemotherapy. The patient successfully received resection of peritoneal dissemination 50 months after the induction of chemotherapy and survived for 10 years.
尽管肝门部胆管癌(HCCA)的预后很差,但多学科治疗仍有使患者获得长期生存的病例。
一名61岁被诊断为HCCA的男性患者被转诊至我院。我们实施了扩大左半肝切除术及尾状叶切除术,并切除了肝外胆管。根据第七版TNM分类,肿瘤分期为T2aN0M0,Ⅱ期。成功实施了R0切除。未进行辅助化疗。38个月后,计算机断层扫描显示有腹膜播散。患者接受替吉奥(S-1)和吉西他滨化疗。腹膜播散成功控制超过50个月。治疗期间,癌胚抗原(CEA)和糖类抗原19-9(CA19-9)水平持续缓慢上升,随后因HCCA腹膜播散导致肠梗阻。患者接受了横结肠及肿瘤结节切除术,肿瘤经病理诊断为HCCA转移。肿瘤标志物降至正常水平,患者已无肿瘤复发6个月。
我们在此报告一例罕见的HCCA患者,R0手术后3年出现复发性腹膜播散,对化疗敏感。患者在化疗诱导50个月后成功接受腹膜播散切除术,并存活10年。